Tremfya drug class?

See the DrugPatentWatch profile for Tremfya

What drug class is Tremfya (guselkumab) in?

Tremfya is a biologic medicine in the IL-23 inhibitor drug class. Specifically, guselkumab targets the p19 subunit of interleukin-23 (IL-23), a cytokine involved in inflammation.

What does that mean for Tremfya’s use?

Because it blocks IL-23 signaling, Tremfya is used for immune-mediated inflammatory diseases where the IL-23 pathway plays a role, including plaque psoriasis.

How does Tremfya fit with other psoriasis biologics?

Tremfya is in the IL-23 inhibitor category, which sits alongside other “biologic-by-pathway” options such as:
- TNF-alpha inhibitors (another inflammation target)
- IL-17 inhibitors (blocks IL-17 cytokines)
- IL-12/23 inhibitors (blocks the IL-12/IL-23 pathways)

What kind of medicine is it (not just the class)?

Tremfya is a monoclonal antibody (a biologic), not a small-molecule drug.